KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900
Drug Appears Well Positioned Vs. Approved Therapies
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.
